KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Receivables (2016 - 2025)

Historic Receivables for West Pharmaceutical Services (WST) over the last 17 years, with Q3 2025 value amounting to $652.5 million.

  • West Pharmaceutical Services' Receivables rose 1516.06% to $652.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $652.5 million, marking a year-over-year increase of 1516.06%. This contributed to the annual value of $575.8 million for FY2024, which is 792.88% up from last year.
  • According to the latest figures from Q3 2025, West Pharmaceutical Services' Receivables is $652.5 million, which was up 1516.06% from $610.3 million recorded in Q2 2025.
  • In the past 5 years, West Pharmaceutical Services' Receivables ranged from a high of $652.5 million in Q3 2025 and a low of $478.2 million during Q1 2021
  • Its 5-year average for Receivables is $538.3 million, with a median of $533.5 million in 2023.
  • In the last 5 years, West Pharmaceutical Services' Receivables skyrocketed by 3726.92% in 2021 and then crashed by 967.97% in 2024.
  • Over the past 5 years, West Pharmaceutical Services' Receivables (Quarter) stood at $503.6 million in 2021, then grew by 3.99% to $523.7 million in 2022, then increased by 1.87% to $533.5 million in 2023, then increased by 7.93% to $575.8 million in 2024, then rose by 13.32% to $652.5 million in 2025.
  • Its last three reported values are $652.5 million in Q3 2025, $610.3 million for Q2 2025, and $569.4 million during Q1 2025.